We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TXNM
301
TXNM Energy Inc
TXNM
$5.97B
| $45M | 0.06% |
791,704
-65,479
| -8% | -$3.84M |
|
302
Roku
ROKU
$22.7B
| $44.9M | 0.06% |
+325,000
| New | +$39.6M |
|
303
Loews
L
$22.2B
| $44.8M | 0.06% |
395,400
+244,700
| +162% | +$26.5M |
|
304
Tenet Healthcare
THC
$21.7B
| $44.7M | 0.06% |
238,848
+146,475
| +159% | +$26.9M |
|
305
Allstate
ALL
$64.1B
| $44.6M | 0.06% |
187,419
+21,500
| +13% | +$4.67M |
|
306
Fox Class B
FOX
$24B
| $44.4M | 0.06% |
948,965
+47,700
| +5% | +$2.65M |
|
|
CHYM
307
Chime Financial
CHYM
$13.1B
| $44.2M | 0.06% |
2,158,328
-213,167
| -9% | -$4.14M |
|
308
Cintas
CTAS
$80B
| $44.1M | 0.06% |
259,237
-88,146
| -25% | -$15.2M |
|
309
Rhythm Pharmaceuticals
RYTM
$6.96B
| $44.1M | 0.06% |
397,000
-328,744
| -45% | -$29.7M |
|
310
Microchip Technology
MCHP
$39.6B
| $44M | 0.06% |
482,300
+132,515
| +38% | +$11.8M |
|
311
Genuine Parts
GPC
$18.6B
| $44M | 0.06% |
372,700
-266,400
| -42% | -$27.8M |
|
312
Federal Realty Investment Trust
FRT
$10B
| $43.1M | 0.06% |
349,419
-105,581
| -23% | -$12.3M |
|
313
McKesson
MCK
$104B
| $43M | 0.06% |
56,904
-14,990
| -21% | -$11.9M |
|
314
Astera Labs
ALAB
$52.1B
| $42.9M | 0.06% |
88,741
-365,000
| -80% | -$96.9M |
|
315
Agilent Technologies
A
$40.8B
| $42.7M | 0.06% |
+321,166
| New | +$39.1M |
|
316
Reinsurance Group of America
RGA
$16B
| $42.5M | 0.06% |
+200,000
| New | +$41.7M |
|
|
MIAX
317
Miami International Holdings
MIAX
$4.26B
| $42.5M | 0.06% |
1,143,920
-103,079
| -8% | -$4.61M |
|
|
JBIO
318
Jade Biosciences
JBIO
$1.21B
| $42.5M | 0.06% |
+1,910,812
| New | +$39.9M |
|
319
Halliburton
HAL
$30.9B
| $42.3M | 0.06% |
1,244,540
+414,200
| +50% | +$16.2M |
|
320
American Healthcare REIT
AHR
$11.7B
| $42.2M | 0.06% |
810,000
+410,000
| +103% | +$20.1M |
|
321
Alto Neuroscience
ANRO
$1.34B
| $42.2M | 0.06% |
1,600,000
+1,215,000
| +316% | +$28.1M |
|
322
Zions Bancorporation
ZION
$9.94B
| $42.1M | 0.06% |
609,003
-173,790
| -22% | -$11M |
|
|
NVO
323
Novo Nordisk
NVO
$197B
| $42.1M | 0.06% |
+877,635
| New | +$37.7M |
|
324
Carvana
CVNA
$52.8B
| $42M | 0.06% |
638,400
+84,900
| +15% | +$6M |
|
325
Nucor
NUE
$58.5B
| $41.9M | 0.06% |
188,000
-17,000
| -8% | -$3.85M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.